Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion

J Infect Dis. 2003 Dec 15;188(12):1794-803. doi: 10.1086/379900. Epub 2003 Dec 8.

Abstract

Immune function was observed for 144 weeks in 643 human immunodeficiency virus (HIV)-infected subjects who (1) had nadir CD4+ cell counts of <50 cells/mm3, followed by a sustained increase to > or =100 cells/mm3 after the initiation of HAART, and (2) were enrolled in a randomized trial of continued azithromycin prophylaxis versus withdrawal for prevention of Mycobacterium avium complex disease. The median CD4+ cell count was 226 cells/mm3 at entry and 358 cells/mm3 at week 144. Anergy (80.2% of patients) and lack of lymphoproliferative response to tetanus toxoid (TT; 73%) after immunization and impaired antibody responses after receipt of hepatitis A (54%) and TT (86%) vaccines were considered to be evidence of impaired immune reconstitution. Receipt of azithromycin did not have an effect on CD4+ cell count but was associated with higher rates of delayed-type hypersensitivity responses to TT (25% of subjects who received azithromycin vs. 15% of those who did not; P=.009) and mumps skin test antigen (29% vs. 17%; P=.001). Although the subjects had only partial responses to immune function testing, the rate of opportunistic infections was very low, and none of the tests was predictive of risk.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acquired Immunodeficiency Syndrome / immunology
  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Bacterial / blood
  • Antiretroviral Therapy, Highly Active
  • Antiviral Agents / therapeutic use*
  • Azithromycin / therapeutic use
  • Biomarkers / analysis
  • CD4 Lymphocyte Count*
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • HIV-1* / isolation & purification
  • Hepatitis A Antibodies / blood
  • Hepatitis A Vaccines / administration & dosage
  • Humans
  • Longitudinal Studies
  • Male
  • Mumps virus / immunology
  • Mycobacterium avium-intracellulare Infection / etiology
  • Mycobacterium avium-intracellulare Infection / prevention & control
  • RNA, Viral / blood
  • Tetanus Toxoid / administration & dosage
  • Tetanus Toxoid / immunology

Substances

  • Anti-Bacterial Agents
  • Antibodies, Bacterial
  • Antiviral Agents
  • Biomarkers
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • RNA, Viral
  • Tetanus Toxoid
  • Azithromycin